Fig. 5
The combination of trametinib and dexamethasone suppresses tumor growth in vivo. a. Human MM1.S cells (107/mouse) were inoculated subcutaneously into the flank of NSG mice, n = 9 mice per group. Once tumors were established, mice were treated with either vehicle, 1 mg/kg/d po trametinib continuously, 1 mg/kg dexamethasone ip (5 d on, 2 d off schedule), or the combination of trametinib and dexamethasone for up to 20 d. Tumor volume was measured by callipers every 3–5 d, and the mean volume per group was expressed as a percentage relative to day 0; error bars represent standard error. Statistical significance was determined using one-way Anova of relative tumor volumes after 13 d of dosing. b. The body weight of the mice from each group in B was measured and the mean per group was expressed as a percentage change from day 0; error bars represent standard error